Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Halozyme Therapeutics Inc

+ Add to Watchlist


13.9300 USD 0.6200 4.66%

As of 20:10:00 ET on 03/27/2015.

Snapshot for Halozyme Therapeutics Inc (HALO)

Open: 13.3600 Day's Range: 13.3100 - 14.1000 Volume: 1,233,840
Previous Close: 13.3100 52wk Range: 6.8800 - 16.5500 1-Yr Rtn: +15.03%

Stock Chart for HALO

No chart data available.
  • HALO:US 13.9300
  • 1D
  • 1M
  • 1Y
Interactive HALO Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for HALO

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.5451
Est. EPS (USD) (12/2015) -0.5090
Est. PEG Ratio -
Market Cap (M USD) 1,764.99
Shares Outstanding (M) 126.70
30 Day Average Volume 1,652,428
Price/Book (mrq) 42.3509
Price/Sale (ttm) 22.7835
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/12/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for HALO

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The Company's platform technology is based on recombinant human hyaluronidase plus additional enzymes. Halozyme applies its technology to its proprietary programs and to partnerships with pharmaceutical companies.

Helen I TorleyPresident/CEODavid A RamsayChief Financial Officer
Athena CountouriotisChief Medical OfficerH Michael Shepard "Mike"VP/Chief Scientific Officer
More Company Profile & Key Executives for HALO

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil